TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04295798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional tDCS
Description: The anode will be placed over F3 and the cathode over the contralateral supraorbital margin. At the beginning of stimulation, the current will be increased from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized tDCS
Description: This intervention will utilize eight gel electrodes with placement and current parameters optimized to the cohort, with the goal of generating an average nE over the left dlPFC of the same size as the one delivered by a conventional montage using sponges. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional Sham
Description: Conventional sham will be used to maximize blinding of conventional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration described above will be used; however, current will be automatically ramped down 60 seconds after ramp-up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Optimized Sham
Description: An active sham will be used in which very low-level currents (0.5 mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. We have shown that this active sham effectively blinds participants and operators to stimulation condition and does not affect functional outcomes.
Study: NCT03301870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Negative Control
Description: Water for Injection, USP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Negative Control
Description: Water for Injection, USP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Placebo
Description: matching placebo gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Placebo
Description: matching placebo gel
Study: NCT00721578

Intervention type: DRUG
Intervention: voriconazole
Description: Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
Study: NCT01905046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given PO
Study: NCT02904629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL)
Description: Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT).

Intervention type: OTHER
Group type: OTHER
Intervention: Control Program
Description: Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
Study: NCT04958993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
Description: radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
Study: NCT04031664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qianjin Capsule of Gynaecology
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qianjin Capsule of Gynaecology
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
Study: NCT00876850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 0796
Description: PTK 0796 100mg for injection; PTK 0796 tablet 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
Study: NCT01542697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal nebulisation of magnesium sulphate
Description: intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intraperitoneal nebulisation of magnesium sulphate
Description: intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
Study: NCT03828903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoprobe
Description: * The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding.
Study: NCT01792713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertaconazole 2% cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00453700

Intervention type: PROCEDURE
Intervention: Trypanosoma cruzi serology
Study: NCT00851981

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TID

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SAMe
Description: 300 mg TID
Study: NCT01730365

Intervention type: PROCEDURE
Intervention: Core biopsy procedure
Description: Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
Study: NCT00924430

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Study: NCT04407975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
Study: NCT05055388

Intervention type: OTHER
Intervention: Multidrug-resistant bacteria
Description: Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
Study: NCT01410175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional scalpel
Description: Use of conventional scalpel to incise the skin and subcutaneous layers.
Study: NCT04339998

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Ultrasonography (POCUS)
Description: The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole
Study: NCT04103307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis cooling
Description: Cooling the blood in the CRRT circuit during delivery
Study: NCT01882426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment algorithm
Description: Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: usual step care practice
Study: NCT02839720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT01157325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial analgesia
Description: Neuraxial analgesia will be given at any time if the parturient requested analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-neuraxial analgesia
Description: No neuraxial analgesia will be given to those who will not want to an analgesia
Study: NCT04816656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePROMs assessment
Description: At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations.
Study: NCT02375841

Intervention type: BEHAVIORAL
Intervention: psychometric tests, questionnaires and neurocognitive assessments
Study: NCT04301128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Patients in the control group were informed same informations verbally and given an education book.
Study: NCT04270682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded CDCA 250 mg TID
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label CDCA 250 mg TID
Description: Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication CDCA 250 mg TID
Description: CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDCA Weight-Based Dose TID
Description: Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
Study: NCT00086359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate, lamivudine, and zidovudine
Description: one pill twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: one pill twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: four pills twice daily
Study: NCT03699163

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sample
Description: Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sample
Description: Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
Study: NCT03407144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study: NCT03368742

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-001
Description: AAV9 vector containing muscle-specific promoter and microdystrophin construct

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-001
Description: AAV9 vector containing muscle-specific promoter and microdystrophin construct
Study: NCT03029182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking+simulated-altitude
Description: Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking (control)
Description: Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
Study: NCT01741025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse Implant System
Description: Placement of iFuse implant system via surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Management
Description: Medications for pain, physical therapy, cognitive behavour therapy
Study: NCT03325868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: Ulipristal 5mg daily by mouth for 12 weeks
Study: NCT00868140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily
Study: NCT02621151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Study: NCT04200755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300Mg Solution for Injection
Description: First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
Study: NCT01712997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Study: NCT04426149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: trehalose
Description: patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
Study: NCT03415451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberscope-Guided Nasogastric tube insertion
Description: Fiberscope-Guided Nasogastric tube insertion
Study: NCT00090233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotateq™
Description: 3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
Study: NCT02865954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iball (mhealth application)
Description: mhealth application and associated device to support activation of the pelvic floor muscles.
Study: NCT03407144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study: NCT01805908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 111In-Pertuzumab + SPECT-CT
Description: 111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
Study: NCT02566785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Intervention
Description: The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.

Intervention type: OTHER
Group type: OTHER
Intervention: Balance Intervention
Description: The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
Study: NCT01394692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative MRI-guided tumor resection
Description: tumor resection with the use of an intraoperative MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard microsurgery
Description: microsurgical tumor resection
Study: NCT01049230

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam radiation
Description: Once a day, 5 days a week (Monday-Friday), for 4-8 weeks